文献速递脑血管病

RECAST试验:急性缺血性卒中后远程缺血适应——Ⅱ期随机安慰剂对照先导试验

RECAST (Remote Ischemic Conditioning After Stroke Trial): A Pilot Randomized Placebo Controlled Phase II Trial in Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2017-03-06

RIC耐受性良好、安全可行,第90天NIHSS评分显著降低,并升高血浆HSP27及其磷酸化水平,提示可能改善神经功能结局,值得开展更大规模试验。

要点

  • 急性缺血性卒中发病24小时内行RIC耐受性良好,52个循环中49个完整完成。
  • RIC组第90天NIHSS中位数1分,假干预组3分,组间差异有统计学意义(P=0.04)。
  • RIC可能通过HSP27相关保护机制改善神经功能结局,需更大规模试验验证。

核心结论

  • 急性卒中后RIC耐受性良好,看起来安全可行,可能改善神经功能结局,保护机制可能由HSP27介导,值得开展更大规模试验。

主要发现

  • 患者于发病后15.8小时(SD 6.2)入组,年龄76.2岁(SD 10.5),血压159/83 mm Hg(SD 25/11),NIHSS评分5分(IQR 3.75-9.25)。
  • RIC组52个循环中49个完整完成,耐受性良好。
  • 假干预组3例发生血管事件(2例缺血性卒中、2例心肌梗死),RIC组无事件(P=0.076,log-rank检验)。
  • 第90天NIHSS评分RIC组中位数1分(IQR 0.5-5),假干预组3分(IQR 2-9.5),差异有统计学意义(P=0.04)。
  • RIC升高血浆HSP27(P<0.05,重复测量双因素方差分析)及磷酸化HSP27(P<0.001),但未改变血浆S100-β、基质金属蛋白酶-9、内源性大麻素或动脉顺应性。

临床怎么用

  • 急性缺血性卒中发病24小时内开展RIC在本试验中耐受性良好且安全可行,但作为先导试验结果尚需更大规模试验验证后方可用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Repeated episodes of limb ischemia and reperfusion (remote ischemic conditioning [RIC]) may improve outcome after acute stroke. METHODS: We performed a pilot blinded placebo-controlled trial in patients with acute ischemic stroke, randomized 1:1 to receive 4 cycles of RIC within 24 hours of ictus. The primary outcome was tolerability and feasibility. Secondary outcomes included safety, clinical efficacy (day 90), putative biomarkers (pre- and post-intervention, day 4), and exploratory hemodynamic measures. RESULTS: Twenty-six patients (13 RIC and 13 sham) were recruited 15.8 hours (SD 6.2) post-onset, age 76.2 years (SD 10.5), blood pressure 159/83 mm Hg (SD 25/11), and National Institutes of Health Stroke Scale (NIHSS) score 5 (interquartile range, 3.75-9.25). RIC was well tolerated with 49 out of 52 cycles completed in full. Three patients experienced vascular events in the sham group: 2 ischemic strokes and 2 myocardial infarcts versus none in the RIC group (P=0.076, log-rank test). Compared with sham, there was a significant decrease in day 90 NIHSS score in the RIC group, median NIHSS score 1 (interquartile range, 0.5-5) versus 3 (interquartile range, 2-9.5; P=0.04); RIC augmented plasma HSP27 (heat shock protein 27; P<0.05, repeated 2-way ANOVA) and phosphorylated HSP27 (P<0.001) but not plasma S100-β, matrix metalloproteinase-9, endocannabinoids, or arterial compliance. CONCLUSIONS: RIC after acute stroke is well tolerated and appears safe and feasible. RIC may improve neurological outcome, and protective mechanisms may be mediated through HSP27. A larger trial is warranted. CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique identifier: ISRCTN86672015.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. England TJ, Hedstrom A, O'Sullivan S, et al. RECAST (Remote Ischemic Conditioning After Stroke Trial): A Pilot Randomized Placebo Controlled Phase II Trial in Acute Ischemic Stroke. Stroke. 2017. PMID: 28265014. doi:10.1161/STROKEAHA.116.016429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。